Skip to main content
Evidence Snapshot

Amine oxidase [flavin-containing] B

CHEMBL2039 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:05:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2039
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Amine oxidase [flavin-containing] B as ChEMBL target CHEMBL2039, mapped to UniProt P27338. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Amine oxidase [flavin-containing] B
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2039
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P27338
Amine oxidase [flavin-containing] B
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Amine oxidase [flavin-containing] B matters

As of 2026-09-13

Amine oxidase [flavin-containing] B is reviewed as Amine oxidase [flavin-containing] B (UniProt P27338); Amine oxidase [flavin-containing] B shows approved-linked disease relevance led by Parkinson disease. 5 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded.; the current evidence base includes 36 approved drugs, 7773 compounds, and 1491 assays, with lead potency reaching pChEMBL 10.8.

Disease context
Parkinson disease

Amine oxidase [flavin-containing] B shows approved-linked disease relevance led by Parkinson disease. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include RASAGILINE MESYLATE, RASAGILINE TARTRATE, SAFINAMIDE.

Start review with Parkinson disease because it currently carries approved-linked support. Linked drugs include RASAGILINE MESYLATE, RASAGILINE TARTRATE, SAFINAMIDE, SAFINAMIDE MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 5 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 36 approved drugs, 7773 compounds, and 1491 assays for this target. The dominant activity type is IC50. CHEMBL348961 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL348961 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine
36 approved pChEMBL 10.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Amine oxidase [flavin-containing] B matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P27338, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Parkinson disease is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

7773
Total Compounds
1491
Total Assays
36
Approved Drugs
IC50: 8649.0, KI: 948.0, EC50: 88.0, KD: 9.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL348961
 10.8 IC50 —
No preferred name
CHEMBL972
 10.8 IC50 Approved
No preferred name
CHEMBL2333930
 9.9 Ki —
No preferred name
CHEMBL4129303
 9.9 IC50 —
No preferred name
CHEMBL3319256
 9.8 Ki —

Approved Drugs

Structure Compound First Approval
SAFINAMIDE
CHEMBL396778
 2015
ISTRADEFYLLINE
CHEMBL431770
 2013
RASAGILINE
CHEMBL887
 2005
RASAGILINE MESYLATE
CHEMBL1201142
 2005
LINEZOLID
CHEMBL126
 2000
PIOGLITAZONE
CHEMBL595
 1999
ROSIGLITAZONE
CHEMBL121
 1999
SELEGILINE
CHEMBL972
 1989
SELEGILINE HYDROCHLORIDE
CHEMBL1200904
 1989
PARGYLINE
CHEMBL673
 1982
MENADIONE
CHEMBL590
 1982
TRANYLCYPROMINE
CHEMBL3989843
 1961
PHENELZINE
CHEMBL1089
 1961
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:05:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2039